Galmed Pharma (GLMD) Tops Q2 EPS by 6c

Galmed Pharma (NASDAQ: GLMD) reported Q2 EPS of ($0.26), $0.06 better than the analyst estimate of ($0.32).

For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.

You May Also Be Interested In

• AeroVironment restates quarterly financials, citing $89M goodwill error
• Alphabet slides over 6% as AI brain drain and SpaceX slump converge
• Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating